Washington-An evolution in the management of bladder cancer, including the use of molecular-based diagnostic testing, may soon make it possible to achieve better outcomes at a lower cost, according to Mark P. Schoenberg, MD. Dr. Schoenberg, associate professor of urology and oncology and director of the bladder cancer research center at the Johns Hopkins School of Medicine in Baltimore, said that a change in some aspects of bladder cancer management is sorely needed.
